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Runs of homozygosity (ROHs) are recognized signature of recessive inheritance. Contributions of ROHs to the genetic architecture of
coronary artery disease and regulation of gene expression in cells relevant to atherosclerosis are not known. Our combined analysis
of 24,320 individuals from 11 populations of white European ethnicity showed an association between coronary artery disease and
both the count and the size of ROHs. Individuals with coronary artery disease had approximately 0.63 (95% CI: 0.4–0.8) excess of
ROHs when compared to coronary-artery-disease-free control subjects (p ¼ 1.49 3 109). The average total length of ROHs was approx-
imately 1,046.92 (95% CI: 634.4–1,459.5) kb greater in individuals with coronary artery disease than control subjects (p ¼ 6.613 107).
None of the identified individual ROHs was associated with coronary artery disease after correction for multiple testing. However, in
aggregate burden analysis, ROHs favoring increased risk of coronary artery disease were much more common than those showing
the opposite direction of association with coronary artery disease (p ¼ 2.69 3 1033). Individual ROHs showed significant associations
withmonocyte andmacrophage expression of genes in their close proximity—subjects with several individual ROHs showed significant
differences in the expression of 44 mRNAs in monocytes and 17 mRNAs in macrophages when compared to subjects without those
ROHs. This study provides evidence for an excess of homozygosity in coronary artery disease in outbred populations and suggest the
potential biological relevance of ROHs in cells of importance to the pathogenesis of atherosclerosis.Introduction
Coronary artery disease (CAD) is a complex, heteroge-
neous polygenic disorder. The largest genome-wide associ-
ation (GWA) meta-analysis conducted to date reported 46
variants associated with risk of CAD.1 All these variants
were identified assuming an additive mode of inheritance
for CAD. It is increasingly recognized that the genetic
architecture of complex disorders, including CAD, is not
a simple composite of variants that operate exclusively un-
der an additive mode of inheritance and that both domi-
nant and recessive components might make important
contributions overseen by conventional GWA studies
(GWASs).
The potential importance of recessively inherited vari-
ants to cardiovascular disease was suggested by several
previous investigations. First, history of parental consan-1Department of Cardiovascular Sciences, University of Leicester, Leicester L
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with increased risk of premature myocardial infarction,
independent of conventional CAD risk factors in a popula-
tion of young adults of South Asian ethnicity.2 Second,
studies in isolated populations with increased parental
relatedness suggested possible associations between homo-
zygosity or its proxies and the risk of both CAD3–5 and
other cardiovascular phenotypes.5,6 These associations
were attributed to the increased levels of homozygosity
and inbreeding depression (reduced biological fitness) in
these populations.7
Homozygosity mapping is a strategy with a potential to
identify and quantify the recessive component of inheri-
tance—long stretches (usually >1 Mb) of consecutive ho-
mozygous genotypes are known as runs of homozygosity
(ROHs).8 In the human genome, ROHs represent ‘‘re-
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Figure 1. Overview of the Project
Strategydescendants.8 Identical by descent, ROHs arise from back-
ground relatedness promoted by demographic processes
that increase homozygosity and reduce population size
(for example, cultural and/or social factors that
favor consanguinity and natural selection).9 A number of
studies clearly demonstrated the presence of relatively
frequent ROHs in outbred populations.8,10–12 However,
only a few studies successfully used the GWA-derived ho-
mozygosity measures to examine their role in the genetic
architecture of complex disorders in outbred popula-
tions.13–15 To the best of our knowledge, there is no study
that examined whether homozygosity is associated with
CAD in such populations and whether individual ROHs
might play a role in regulation of gene expression within
cells of key importance to atherosclerosis.
The primary goal of this project was a comprehensive
analysis of association between genome-wide homozy-
gosity measures and CAD in individuals of white Euro-
pean ancestry. A secondary analysis was undertaken
to identify and quantify consensus ROHs overlapping
across studies and explore their potential relevance to
CAD individually and at the aggregate level. Finally, we
explored the association of consensus ROHs and geneThe American Journal of Human Gexpression in human monocytes
and macrophages. The overview of
the strategy used is included in
Figure 1.
Subjects and Methods
Study Cohorts
Genetic information on 24,320 biologi-
cally unrelated individuals (all of white
European ancestry) was collected from 11
previous GWASs.16 A total of 12,123 indi-
viduals with CAD and 12,197 CAD-free
control subjects from the Wellcome Trust
Case Control Consortium (WTCCC),17
the German Myocardial Infarction Family
Studies (GerMIFSI, II, and III),17–19 Inter-
Heart Study (ITH),20 the Ottawa Heart
Genomics Studies (OHGS-A, B, and C),21
PennCATH,22 Cleveland Clinic Gene
Bank (CCGB), and Duke Cathgen Study
(DUKE) were included in the analysis. In
brief, six studies (GerMIFSI, GerMIFSII,
GerMIFSIII, OHGS-A, PennCATH, and
WTCCC) were derived from the original
CARDIoGRAM Consortium.16 Five addi-
tional studies (CCGB, DUKE, ITH, OHGS-B,
and OHGS-C), not originally a part of
the Consortium,16 agreed to participate,
bringing a total number of examined pop-
ulations to 11. Further information on therecruitment and phenotyping of the studies is available in the Sup-
plemental Data including Table S1.
Genotyping and Imputation
DNAwasextracted fromperipheralblood inall studies exceptBritish
1958 Birth Cohort (58BC), which contributed control subjects to
WTCCC.23 Indeed, in these subjects DNA was extracted from cell
lines.23 InformationonSNPs included in the analysis is shown inTa-
ble S2.Only imputed genotypes that could be calledwith a posterior
probability of R90% were included in the analysis. SNPs were
removed from further analysis if their minor allele frequency
(MAF) was <1%, their genotype distribution deviated from Hardy-
Weinberg equilibriumwith p< 0.001, or the genotypepost-imputa-
tion call rate was %95%. Individual samples were removed from
further analysis if the sample call ratewas%95%.All quality-control
filters were applied individually at the cohort level.
ROH Identification
A number of ROH definitions and methods of their detection have
been proposed.12,24–26 In this project ROHs were identified via the
‘‘Runs of Homozygosity’’ program, implemented in PLINK
(v.1.07).27 The adopted PLINK parameters are similar to the ones
used in previous publications.28,29 A sliding window of 50 SNPs in
5,000 kb length region was used to scan the genome. To prevent
underestimating the number and size of ROHs, one heterozygoteenetics 97, 228–237, August 6, 2015 229
and two missing calls in each window were permitted to allow for
possible genotyping errors within a stretch of truly homozygous
SNPs or other sources of artificial heterozygosity. A SNPwas counted
as a part of a ROH if>5%ofwindows spanning itwerehomozygous.
Theseparameterswere selected tominimize theprobability of awin-
dow being called homozygous by chance. The existence of linkage
disequilibrium (LD) blocks in DNA means that relatively short
ROHs (those spanning from tens to hundreds of kilobases) are very
prevalent across the genome.30–33 In order to exclude these very
common short tracts of homozygous SNPs, the minimum length
for a ROH was set at 1 Mb, as used by several other studies.13,28
Two additional parameters were added to ensure that estimates
were not artificially inflated by apparently homozygous tracts in
sparsely covered genomic regions. First, the required minimum
SNP density was set to 50, meaning at least 1 SNP had to be present
per 50 kb of DNA, and second, themaximum distance between two
consecutive homozygous SNPs was set to 100 kb. To ensure that the
analysis captures only regions that are entirely homozygous be-
tween the first and the last SNP, a threshold for theminimumnum-
ber of SNPs constituting a ROH was selected. In line with previous
studies on homozygosity of complex disorders, theminimumnum-
ber ofhomozygous SNPs toqualify as aROH in thisprojectwas set to
100.13Therewerenomajordifferences inthe resultsofROHanalyses
conducted under different thresholds of ROH calculation parame-
ters in our pilot sensitivity analyses inWTCCC (data not shown).Calculation of Homozygosity Measures
The following measures of homozygosity were calculated in each
study: (1) the average number of ROHs, (2) the total and average
length of ROHs, and (3) the proportion of the autosomal genome
covered by ROHs (FROH).34 The total number of ROHs was
defined as the sum of all ROHs per individual. The average ROH
number was calculated as the total number of runs divided by
the total number of subjects. The average total ROH length is
the sum of the length of each individual ROH per participant
and was calculated by dividing the total ROH length by the num-
ber of individuals. The average ROH length was calculated by
dividing the total genomic length of the ROHs by the total num-
ber of ROHs per individual. To calculate FROH, a percentage of ho-
mozygosity was calculated by summing ROHs >1 Mb across the
covered autosomal genome and dividing by the total autosomal
base pairs represented in the SNP data.8 Specifically, the summed
length of identified ROHs were divided by a factor of 2,772.7
and subsequently converted to a percent by multiplying the divi-
dend by 100. A factor of 2,772.7 is the number of megabases
covered by SNPs after imputation, which was calculated by sum-
ming the distance between the first and the last available consec-
utive SNP on each chromosomal arm for each of the 22 autosomes.
Examination of the FROH distribution revealed that it was highly
right-skewed. To facilitate the analysis, data were transformed via a
rank-based inverse normal transformation.
Assuming the dispersion of general homozygosity indices
similar to the observed measures, a study with 24,320 subjects
including 12,123 individuals with CAD and 12,197 CAD-free con-
trol subjects has ~80% power to detect a case-control difference
of ~0.25 in ROH number, ~4.7 kb in average ROH length, and
~520 kb in average total ROH length.Definition of Consensus ROH
It is not expected that a ROH will start and end at the same base
pair positions for each individual, so we needed to define the230 The American Journal of Human Genetics 97, 228–237, August 6size of the overlapping ROHs. For each study, the size of a ROH
was determined as the consensus region of a homozygous run of
SNPs (>1 Mb in length) overlapping between at least five individ-
uals within a cohort. Consensus ROHs were then separated into
groups and the numbers of case and control subjects with the
ROH were counted via PLINK in each cohort. This ROH definition
was applied to each study and provided a set of consensus ROHs.
Information on the size, location (start/end of the consensus
ROH), and the number of SNPs in each consensus ROHwere calcu-
lated for each study.Identification of Overlapping Consensus ROHs
We combined these consensus ROHs from individual studies to
identify regions overlapping between studies. This was achieved
by comparing the positions of the consensus ROHs from each
study against those from all other cohorts; this was repeated until
we had identified how many studies overlapped for each individ-
ual consensus ROH. We allowed each individual study consensus
ROH to overlap with more than one consensus ROH from another
individual study to allow longer ROHs to be included in multiple
overlapping consensus ROHs. We then combined the numbers of
case and control subjects across studies with the overlapping
consensus ROH.Statistical Analysis
Genetic Architecture of Homozygosity Measures
We generated QQ plots to assess the quality of the data in each
individual study. A regression analysis using individual level
participant data adjusting for cohort, sex, and age where
possible was performed for the homozygosity measures. Age
and sex were the only additional variables available in all
studies. Additional sensitivity analyses using a rank-based in-
verse normal transformation of general homozygosity measures
was performed to assess the influence of outliers. Further sensi-
tivity analyses were conducted to exclude the effect of a cohort
with different cell sources of DNA in case and control subjects.
Finally, to account for potential heterogeneity between individ-
ual studies in the combined analysis of data, we first fitted a
mixed model with cohort as a random effect in the analysis of
association between CAD and four homozygosity measures. Sec-
ond, we introduced a term of interaction between cohort and
the outcome (CADxcohort or FROHxcohort) into the regression
models that examined association between CAD and each of
four homozygosity measures. Further sensitivity association an-
alyses were conducted for those measures of homozygosity that
showed some evidence of heterogeneity between populations
(defined as significance of interaction term at p < 0.05). These
sensitivity analyses examined the magnitude and the signifi-
cance of association between homozygosity measures and CAD
after exclusion of cohorts with statistically significant interac-
tion terms. Each of the sensitivity analyses was conducted via
regression models fitted with cohort as both fixed and random
effect.
Association Analysis between Overlapping Consensus ROHs and CAD
Overlapping consensus ROHs across populations were analyzed
via logistic regression with CAD as the response with adjustment
for sex, age where possible, study, and ROH (presence or absence)
status (as the predictor of interest). To account for multiple testing,
we used a Bonferroni correction in this analysis (p ¼ 2.943 106).
A binomial test was used to examine whether there was a devia-
tion from the expected distribution (50/50) of overlapping, 2015
Table 1. Differences in Homozygosity Measures between Individuals with Coronary Artery Disease and Control Subjects: Combined
Analysis
Measure
Un-adjusted Analysis Age-Adjusted Analysis Age- and Sex-Adjusted Analysis
b-coefficient/OR 95% CI p Value b-coefficient/OR 95% CI p Value b-coefficient/OR 95% CI p Value
Average
ROH
number
0.39 0.20,
0.57
3.92 3 105 0.67 0.47,
0.86
4.12 3 1011 0.63 0.42,
0.83
1.49 3 109
Average
ROH
length (kb)
2.51 0.80,
5.82
0.14 5.19 1.64,
8.75
0.004 4.50 0.85,
8.15
0.016
Average total
length of
ROHs (kb)
688.11 314.44,
1,061.78
3.08 3 104 1,145.15 743.95,
1,546.35
2.24 3 108 1,046.92 634.37,
1,459.48
6.61 3 107
FROH 1.07 1.03,
1.10
8.63 3 105 1.14 1.10,
1.18
2.21 3 1013 1.13 1.09,
1.17
1.57 3 1011
Data for number, average length, and total length of homozygosity runs (ROHs) are b-coefficients (with respective confidence intervals and level of statistical
significance [p value] from regressing homozygosity measures on case-control status with adjustment for cohort, age, and sex, where appropriate); data on
FROH (proportion of autosomal genome in ROHs) are expressed as odds ratios (OR) of coronary artery disease risk (with confidence intervals and level of statistical
significance) with adjustment for cohort, age, and sex (where appropriate). 95% CI indicates 95% confidence intervals.consensus ROHs showing increased (OR > 1) and decreased
(OR < 1) risk of CAD.
Gene Expression Analysis and ROHs
Approximately 600,000 directly genotyped SNPs were available in
the Cardiogenics Study. For the sake of consistency with the other
examined studies, imputation was performed based on HapMapII
CEU build 36. The ROH definitions and the principles of genome-
wide homozygosity analysis were similar to the one conducted in
Stage A of this project (Figure 1).
Information on gene probes underneath consensus ROHs in
monocytes (758 individuals) and macrophages (614 individuals)
was extracted in silico from the microarray-based experiment
conducted in the Cardiogenics Study reported previously.35,36
The comparative analysis was conducted at the probe level in
cis, assessing only genes within 500 kb of a ROH, by using linear
regression adjusted for age, sex, recruitment center, and the status
(presence or absence) of consensus ROHs. After quality-control fil-
ters, information on 11,336 gene probes was available to examine
differences in expression of genes in monocytes and macrophages
between individuals with ROHs versus those without ROHs. Re-
sults were first adjusted by genomic control. We then calculated
false discovery rate (FDR) q values for all identified ROH-mRNA as-
sociations using amethod by Storey and Tibshirani appropriate for
correlated gene expression data.37 Associations with a FDR q value
of < 0.01 were considered statistically significant.
All statistical analyses were undertaken in STATA v.12.Results
General Characteristics of the Study Cohorts
A total of 24,320 individuals of European ancestry from 11
populations were included. The key characteristics of the
cohorts (including definition of CAD in each study) used
in the homozygosity analysis are summarized in Table S1.
General Characteristics of Homozygosity Measures
The summary and distribution of homozygosity measures
in each population are shown in Table S3 and Figure S1. AThe Amerjoint analysis of all subjects revealed on average 31.84 5
8.44 ROHs in autosomal DNA. The stretches of homozy-
gous SNPs had an average length of 1,360.585 127.19 kb
and they covered on average a total length of 43.67 5
15.59 Mb. The number and length of ROHs per individual
were in the range of 4–276 (number) and 1–29.4 Mb
(length) in the overall sample.Comparison of Homozygosity Measures between
Individuals with CAD and CAD-Free Control Subjects
The distribution of average ROH number, average ROH
length, and average total ROH length for case and control
subjects in each population are shown in Figure S2. As a
general trend, the distributions of homozygosity measures
were comparable between case and control subjects from
the same populations.
The combined analysis of 11 populations revealed sta-
tistically significant differences in homozygosity levels
between individuals with CAD and control subjects after
adjustment for study, sex, and age (Table 1). On average,
individuals with CAD had 0.63 ROHs more than control
subjects (b ¼ 0.63, 95% CI: 0.42–0.83, p ¼ 1.49 3 109).
The length of ROHs in individuals with CAD was on
average 4.50 kb longer compared to control subjects
(b ¼ 4.50, 95% CI: 0.85–8.15, p ¼ 0.016). The average to-
tal length of ROHs in the autosomal genome was
1,046.92 kb greater in individuals with CAD than control
subjects (b ¼ 1,046.92, 95% CI: 634.37–1,459.48, p ¼
6.61 3 107). Logistic regression analysis revealed that
every 1 SD increase in FROH was associated with a 13%
increase in CAD risk (OR ¼ 1.13, 95% CI: 1.09–1.17,
p ¼ 1.57 3 1011). The association results were similar us-
ing cohort as both fixed (Table 1) and random (Table S4)
effect.
We have conducted a number of further sensitivity
analyses to confirm robustness of our findings. First, by
using a rank-based inverse normal transformation forican Journal of Human Genetics 97, 228–237, August 6, 2015 231
Table 2. Frequency of Overlapping Consensus ROHs with a Potentially Increasing or Decreasing Risk of Coronary Artery Disease: Analysis
Stratified on Number of SNPs in Overlapping Consensus ROHs
Overlapping Consensus ROHs Expected Observed p Value
Overall [ CAD risk 50% (8,494.5) 54.6% (9,278) 2.69 3 1033
Y CAD risk 50% (8,494.5) 45.4% (7,711)
Group 0 [ CAD risk 50% (926) 55.1% (1,020) 1.37 3 105
2–9 SNPs Y CAD risk 50% (926) 44.9% (832)
Group 1 [ CAD risk 50% (3,009) 53.4% (3,214) 1.33 3 107
10–49 SNPs Y CAD risk 50% (3,009) 46.6% (2,804)
Group 2 [ CAD risk 50% (1,704) 55.0% (1,876) 4.09 3 109
50–99 SNPs Y CAD risk 50% (1,704) 45.0% (1,532)
Group 3 [ CAD risk 50% (2,855.5) 55.5% (3,168) 1.39 3 1016
100þ SNPs Y CAD risk 50% (2,855.5) 44.6% (2,543)
Data are counts and percentages. Overlapping consensus ROHs were classified as increasing ([) and decreasing (Y) risk of coronary artery disease (CAD) based on
the magnitude of their odds ratio (OR) for CAD; OR > 1.0 indicates increasing risk of CAD and OR < 1.0 indicates decreasing risk of CAD. p value indicates level of
statistical significance from binomial test, and the size (and thus the number of SNPs) in each overlapping consensus ROH depends on the length of the consensus
sequence common for the studies: from 2 to 100þ SNPs were identified in these regions.ROH number, average, and total length, we confirmed
that outliers had no noticeable influence on the estimates
of association between CAD and these homozygosity
measures (data not shown). Second, exclusion of a pro-
portion of WTCCC controls whose DNA was extracted
from cell lines (the British 1958 Birth Cohort) rather
than peripheral blood (like the rest of case and control
subjects) had no major impact on the significance of
our data (Table S5). Third, accounting for some heteroge-
neity between populations in the analysis of association
between CAD and average ROH number and FROH did
not affect the significance of our findings. Indeed, exclu-
sion of cohorts with significant interaction terms did
not reduce the magnitude or statistical significance of
association between CAD and average ROH number or
FROH (Table S6). In fact, correcting for the residual het-
erogeneity has increased the statistical significance of
the findings.
Identification and Characterization of the
Overlapping Consensus ROHs
A joint analysis of all consensus ROHs identified across 11
examined populations revealed a total of 16,989 overlap-
ping consensus ROHs shared by at least two populations.
An example of an overlapping consensus ROH segment
is illustrated in Figure S3. These overlapping consensus
ROHs were further classified into four groups based on
their SNP enrichment (Table S7).
Association between Individual Overlapping
Consensus ROHs and CAD
After correction for multiple testing calculated at p ¼
2.94 3 106, none of the 16,989 identified overlapping
consensus ROHs were associated with CAD. The most sig-
nificant association between an overlapping consensus
ROH on chromosome 3 (present in 138 subjects from 7232 The American Journal of Human Genetics 97, 228–237, August 6populations) was assigned a nominal level of statistical sig-
nificance of p ¼ 1.993 104. Details of the ten most statis-
tically significant overlapping consensus ROHs are listed in
Table S8.
Overlapping Consensus ROHs and CAD: Aggregate
Burden Analysis
Based on the magnitude of crude OR from the analysis of
association with CAD, each of 16,989 overlapping
consensus ROHs was classified as potentially increasing
(OR > 1.0) or decreasing (OR < 1.0) risk of CAD. Under
a null hypothesis of no association between overlapping
consensus ROHs and CAD, the distribution of overlap-
ping consensus ROHs between both categories should be
even (50/50). However, a clear deviation from this
expected distribution was apparent: there was an excess
of overlapping consensus ROHs increasing risk of CAD
over those classified as potentially protective (55/45), a
difference inconsistent with chance (p ¼ 2.69 3 1033)
(Table 2). The same over-representation of ROHs
increasing the risk of CAD was apparent in each category
of overlapping consensus ROHs after stratification
based on number of SNPs in each consensus segment
(Table 2).
Association between Consensus ROHs and Gene
Expression Measures in Human Monocytes and
Macrophages
To explore whether the presence of individual consensus
ROHs is related to expression of genes that map onto
or near specific ROHs, we combined genome-wide
consensus ROHs with data from monocyte and macro-
phage transcriptome profiling in the Cardiogenics Study.
In brief, 11,336 gene probes were expressed in human
monocytes and macrophages. A total of 3,223 consensus
ROHs were identified in the genome-wide homozygosity, 2015
Figure 2. Analysis of Association between the Presence of Consensus ROHs andGene Expression in the Cardiogenics Study: Genome-
wide Signal-Intensity Plot
(A) Human monocytes.
(B) Human macrophages.
The y axis shows the logarithmic level of statistical significance (p value) for association of each consensus ROH with expression. The
x axis shows 22 autosomal chromosomes in numerical order.analysis of Cardiogenics. After FDR-based correction
for multiple testing (q value < 0.01), 44 consensus
ROH-mRNA associations retained their statistical sig-
nificance in monocytes (Figure 2, Table S9). The most
significant association was identified between ROH on
chromosome 16 and expression of dihydrouridine
synthase 2 (DUS2L [MIM: 609707])—subjects with this
consensus ROH had on average 0.23 (95% CI: 0.19–
0.26) lower expression of DUSL2 in monocytes when
compared to those without this ROH after adjustmentThe Amerfor age, sex, and center of recruitment (p ¼ 5.74 3
1030, q ¼ 6.51 3 1026). After the correction for multi-
ple testing, 17 consensus ROH-mRNA associations re-
tained their statistical significance in macrophages
(Figure 2, Table S10). The most significant association
was identified on chromosome 3 with the expression of
WD repeat domain 6 (WDR6 [MIM: 606031])—subjects
with this consensus ROH had on average 0.19 (95% CI:
0.14–0.25) lower expression of WDR6 in macrophages
when compared to those without this ROH afterican Journal of Human Genetics 97, 228–237, August 6, 2015 233
adjustment for age, sex, and center of recruitment (p ¼
4.57 3 1010, q ¼ 5.18 3 106).Discussion
Our analysis of homozygosity produced several important
findings. First, we provided evidence for enrichment of
homozygosity in individuals with CAD when compared
to CAD-free control subjects. Second, although none of
the identified overlapping consensus ROHs was associated
with CAD individually, their aggregate burden analysis
showed over-representation of overlapping consensus
ROHs favoring increased risk of CAD when compared to
those showing the opposite direction of association with
CAD. Taken together, these data indicate that homozygos-
ity might be an important risk factor for CAD and suggest
that the accumulation of multiple recessive variants might
be an important component of the genetic architecture of
CAD. Finally, the analysis of humanmonocyte and macro-
phage transcriptomes suggested that many individual
consensus ROHs might carry biologically active variants
with a potential to affect expression of genes located either
within these ROHs or in their close proximity.
Our analysis of homozygosity measures provided further
evidence for the presence of common ROHs in outbred
populations.8,11,12 Detection of ROHs in homozygosity
mapping tends to vary along the genome due to differ-
ences in informativeness of haplotypes and differences in
haplotype genealogies.38 The relative performance of ho-
mozygosity mapping is influenced by population demo-
graphic processes and the extent of selection against causal
variants.38 ROHs were widely distributed across the entire
genome and were present on each human autosome. The
number of ROHs was a function of chromosomal length,
and the average ROH number and average total length of
ROHs were dependent on chromosomal size, showing
good agreement with previous studies in populations of
European ancestry.29
Inbred individuals tend tohavehigher rates of congenital
disorders and lower survival and fertility rates (inbreeding
depression).7,39 FROH is a measure of inbreeding effects
and correlates most highly with the homozygous muta-
tional load, the putative causal mechanism underlying
inbreeding depression.34 This homozygosity measure has
low prediction error variance, especially when SNP density
is high.14 However, given the small variation in genome-
wide FROH in unrelated individuals, large sample sizes are
necessary to detect inbreeding depression for likely effect
sizes.14 Previous studies investigating the effects of FROH
on human complex traits with relatively small sample sizes
have failed to find significant inbreeding effects,28,34,40–43
most probably because they were underpowered. Further-
more, very small studies (n< 1,000) that did find significant
inbreeding depression effects using FROH13 might greatly
overestimate the size of effects. The sample size of this study
provides a well-powered tool for finding signatures of234 The American Journal of Human Genetics 97, 228–237, August 6homozygosity on CAD risk. As a result, we were able to
quantify a measure of global homozygosity in relation to
CAD—an estimated 13% increase in CAD risk per 1 SD
increase in FROH.
We appreciate that our analysis did not reveal statisti-
cally significant associations between individual overlap-
ping consensus ROHs and CAD, possibly because many
of them have low population frequency and this can affect
the power of the analysis. Indeed, although some overlap-
ping consensus homozygous sequences are common and
might coincide with previously identified ROH islands29
or long haplotypes, a majority of the consensus regions
overlapping across populations occur in low frequencies
(<5%) or indeed are very rare (<1%).
However, overlapping consensus ROH-based analysis
provided several important insights into the genetic archi-
tecture of CAD. First, it revealed that none of the identified
overlapping consensus regions were exclusive to CAD case
subjects. Second, it showed that none of the identified
overlapping consensus regions have been implicated in
previous CAD GWASs. This is perhaps not surprising given
that GWASs have analyzed data under an additivemodel of
inheritance, whereas ROH analysis assumes recessivemode
of inheritance. Third, the aggregate burden analysis of
overlapping consensus ROHs showed an excess of the re-
gions favoring increased risk of CAD over those that tend
to protect against it, supporting the hypothesis that indi-
viduals with CAD might have accumulated more recessive
variants than controls. This cumulative excess of ROHs
with dispersed distribution across the genome rather
than effects of specific variants recessively inherited by a
subset of affected individuals44 appears a more likely driver
for the increased homozygosity in CAD. Additional work is
needed to unravel the exact synergistic effects of multiple
recessive variants on global homozygosity levels and their
relevance to CAD. Finally, within the constraints of inter-
pretational limitations discussed above, the overlapping
consensus ROH-based analysis provides a useful example
of comparing individual ROHs across studies.
Our study also examined the effects of consensus ROHs
ontheexpressionofgenes inhumancells relevant toathero-
sclerosis. One of themost obvious explanations for the bio-
logical meaning of the associations between consensus
ROHs and the expression of genes underneath them or in
close proximity to them is that they are signatures of func-
tionally active recessive variants with a potential to affect
transcription in monocytes and macrophages. Neither of
the identified genes showed the immediately obvious bio-
logical relevance to atherosclerosis or CAD. Indeed, the
most significant association in monocytes was identified
with the expression of DUS2L. This gene encodes a cyto-
plasmic protein that catalyzes the conversion of uridine res-
idues to dihydrouridine in theD-loop of tRNA. The encoded
protein might affect the rate of translation by inhibiting an
interferon-induced protein kinase.45 The most significant
association in macrophages was with the expression of
WDR6. This gene encodes a member of the WD repeat, 2015
protein family implicated in regulation of cell growth ar-
rest.46 Future studies will be necessary to elucidate the mo-
lecular and clinical mechanisms of these associations.
We shouldmention that definition of ROHs varies across
studies in the published literature, which makes their com-
parisons difficult.47 In order to combine the ROH informa-
tion across several studies, we made use of both directly
genotyped and imputed SNPs to increase the coverage of
the genome and extract the maximum possible informa-
tion. The use of imputed SNPs helped to increase similarity
of genomic coverage across studies and made the data
more comparable because ROHs were defined based on
similar SNP sets. We applied a requirement that a genotype
could be called only if the posterior probability was >90%
and then applied call rate filters to remove SNPs, which
were called in <95% of individuals. This has an effect of
thinning the imputed data but is not equivalent to having
the same effect as LD pruning. We chose not to use LD-
driven elimination of SNPs from our datasets because
such pruning might act as a potential confounder in
comparative ROH analyses of different populations—the
local level of LD determines the effective number of SNPs
used for ROH definition.29 Although LD pruning brings
the benefit of selecting independent SNPs, previous studies
have shown that LD-based pruning can reduce informa-
tiveness of datasets and lead to a loss in power to detect
ROHs.48 Many recently published studies defined a ROH
to include a minimum of 50–65 SNPs for pruned and
unpruned data.44,49–53 Therefore, we have accounted for
imputation-driven increase in SNP density by extension
of the minimal number of SNPs that define a ROH to 100.
We acknowledge the potential confounding of unde-
tected clonal mosaicism manifesting as chromosomal ab-
normalities (i.e., uniparental disomy) that might mirror
runs of homozygosity in GWASs based on DNA extracted
from peripheral blood. Indeed, both Laurie et al.54 and
Jacobs et al.55 revealed that clones of cells with such chro-
mosomal anomalies are present in free-of-cancer (appar-
ently healthy) individuals included in GWASs and that
increasing age is associated with augmented risk of clonal
mosaicism in the human genome.54–56 This in essence
means that comparative analysis of homozygosity in
DNA extracted from peripheral blood between case and
control subjects that differ in age might be potentially
affected by increased rates of such clonal chromosomal ab-
normalities (and thus inflated homozygosity measures) in
the older group. Although we were not able to directly
quantify the prevalence of such abnormalities in the
populations included in this project, we reason that a
correction for such a potential confounding would further
increase rather than reduce the significance of our associa-
tion findings. Indeed, CAD-free control subjects were
generally much older than individuals with CAD in a ma-
jority of studies included in this project. Thus, a correction
for age-driven clonal mosaicism-related chromosomal ab-
normalities interpreted as ROHs in genome-wide analysis
would reduce the rates of homozygosity in the olderThe Amergroups (mostly CAD-free control subjects), further
increasing the case-control difference. To this end, we
also acknowledge the different cell types as a source of
DNA for experiments in one of 11 cohorts included in
this project. Indeed, a part of control group in WTCCC
(58BC cohort) was genotyped using DNA extracted from
cell lines.23 DNA extracted from cell lines might be associ-
ated with higher rates of chromosomal aberrations that
might resemble ROHs in GWASs. However, we confirmed
that exclusion of those subjects had no major effect on
findings from our analysis of association between CAD
and homozygosity measures.
Conclusions
Genome-wide homozygosity analysis revealed statistically
significant differences in the genome-wide homozygosity
levels between individuals with CAD and CAD-free control
subjects. The aggregate burden analysis of overlapping
consensus ROHs showed their over-representation among
subjects with CAD, suggesting that accumulation of reces-
sive variants might increase the risk of CAD. Finally, the
presence of associations between consensus ROHs and
gene expression in human monocytes and macrophages
suggest that many individual ROHs might be signatures
of biologically active recessive variants with a potential
to regulate transcription.Supplemental Data
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